4 Healthcare Stock Stories For a Midweek Investment Checkup

Eli Lilly and Co. (NYSE:LLY): Closing price $53.11

Eli Lilly and Boehringer Ingelheim Pharmaceuticals have enrolled the initial patient into a cardiovascular and renal outcomes trial for linagliptin (Tradjenta) tablets. The trial will examine the effect of the once-daily dipeptidyl peptidase-4 inhibitor linagliptin on cardiovascular and renal outcomes in adults suffering from type 2 diabetes at risk of major macro and microvascular events. The study should be completed in 2018.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LLY

Abbott Laboratories (NYSE:ABT): Closing price $36.63

On Wednesday, Abbott announced promising results from a study evaluating its High Sensitive Troponin-I (hsTnI) assay presented at the 2013 American Association for Clinical Chemistry annual meeting in Houston. The study, run by researchers at Brigham and Women’s Hospital, showed that Abbott’s hsTnI test, which is presently for research-use only in the United States, could help physicians forecast which patients presenting with symptoms of a heart attack, such as severe chest pain, are at a higher risk for suffering a heart attack 30 days later.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ABT-20130731

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS): Closing price $28.85

Isis said that it has received a milestone payment of $2 million from GlaxoSmithKline (NYSE:GSK). The payment was connected with the advancement of the ongoing randomized, double-blind, placebo-controlled, fifteen-month international phase II/III study, which is studying the use of ISIS-TTR in patients with familial amyloid polyneuropathy. The FDA has granted both fast track designation and orphan drug status for ISIS-TTR in the FAP indication. The company is developing ISIS-TTR working jointly with Glaxo for the potential treatment of transthyretin amyloidosis.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ISIS-20130731

Baxter International Inc. (NYSE:BAX): Closing price $73.04

Baxter and JW Holdings announced Wednesday that they have formed an exclusive distribution and license agreement for parenteral nutritional products that contain a novel formulation of omega 3 lipids. With this arrangement, Baxter will complement its global parenteral nutrition portfolio, and supply worldwide commercial capabilities and clinical development. Through the terms, Baxter will enjoy exclusive rights to co-develop and distribute the products globally, with the exception of Korea. The accord includes a $25 million up-front payment that will be recorded as a special pre-tax in-process research and development charge in the third quarter.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BAX-20130731

Don’t Miss: Obamacare May Cause Some Workers to Quit, But That’s OK.